[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@chuminhua432 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::3643934180.png) @chuminhua432 Minhua Chu

Minhua Chu posts on X about china, hong kong, approved, has been the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.

### Engagements: XXXXX [#](/creator/twitter::3643934180/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3643934180/c:line/m:interactions.svg)

- X Week XXXXXX +67%
- X Month XXXXXX +18%
- X Months XXXXXXX +61%
- X Year XXXXXXX +436%

### Mentions: XX [#](/creator/twitter::3643934180/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3643934180/c:line/m:posts_active.svg)

- X Week XX no change
- X Month XXX -XX%
- X Months XXX no change
- X Year XXX +112%

### Followers: XXXXX [#](/creator/twitter::3643934180/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3643934180/c:line/m:followers.svg)

- X Week XXXXX +0.28%
- X Month XXXXX +2.20%
- X Months XXXXX +51%
- X Year XXXXX +136%

### CreatorRank: XXXXXXX [#](/creator/twitter::3643934180/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3643934180/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::3643934180/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXX% [countries](/list/countries)  XXXX% [finance](/list/finance)  XXXX% [travel destinations](/list/travel-destinations)  XXXX% [vc firms](/list/vc-firms)  XXXX% [cryptocurrencies](/list/cryptocurrencies)  XXXX% [exchanges](/list/exchanges)  XXXX% [technology brands](/list/technology-brands)  XXXX% [currencies](/list/currencies)  XXXX%

**Social topic influence**
[china](/topic/china) 5.05%, [hong kong](/topic/hong-kong) #534, [approved](/topic/approved) 2.02%, [has been](/topic/has-been) 2.02%, [$onc](/topic/$onc) #1, [kong](/topic/kong) 1.52%, [ipo](/topic/ipo) 1.52%, [hong kong stock exchange](/topic/hong-kong-stock-exchange) 1.52%, [$bmy](/topic/$bmy) 1.01%, [$legn](/topic/$legn) XXXX%

**Top accounts mentioned or mentioned by**
[@knielsen2000](/creator/undefined) [@yaireinhorn](/creator/undefined) [@bioebro](/creator/undefined) [@phototogboy](/creator/undefined) [@sss124545852740](/creator/undefined) [@grok](/creator/undefined) [@yahoofinance](/creator/undefined) [@fiercebiotech](/creator/undefined) [@ceo_culley](/creator/undefined) [@exclamotite69](/creator/undefined) [@drcm4t](/creator/undefined)

**Top assets mentioned**
[One Cash (ONC)](/topic/$onc) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Johnson & Johnson (JNJ)](/topic/$jnj) [Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt) [AbbVie Inc (ABBV)](/topic/$abbv) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Eli Lilly and Company (LLY)](/topic/$lly) [Pfizer, Inc. (PFE)](/topic/$pfe) [GSK plc (GSK)](/topic/$gsk) [Sanofi (SNY)](/topic/sanofi) [Synthetify (SNY)](/topic/$sny) [Merck & Co., Inc. (MRK)](/topic/$mrk)
### Top Social Posts [#](/creator/twitter::3643934180/posts)
---
Top posts by engagements in the last XX hours

"A rumor suggests that $BMY may be poised for a major adjustment in its #China operations. According to the content of a leaked email BMS has signed an agreement to sell its XX% stake in Shanghai Bristol-Myers Squibb Pharmaceutical Co. Ltd. (SASS) along with several related products manufactured and sold exclusively in the mainland China marketincluding Baraclude (entecavir) Bufferin Theragran Monopril (fosinopril) and Velosef (cephradine)to an affiliate of Hillhouse Investment Group (Highland Capital). The transaction is expected to be completed in early 2026 with the specific deal amount yet"  
[X Link](https://x.com/chuminhua432/status/1966779876482171286) [@chuminhua432](/creator/x/chuminhua432) 2025-09-13T08:23Z 2905 followers, 13.8K engagements


"Legend Biotech $LEGN registered a Phase I clinical trial for LUCAR-G19 to treat autoimmune diseases. NCT07049081 The study plans to enroll XX patients with relapsed or refractory autoimmune diseases including systemic lupus erythematosus systemic sclerosis ANCA-associated vasculitis inflammatory myopathy Takayasu arteritis IgG4-related disease. The study has X sites in #China. LUCAR is a non-gene-editing allogeneic CAR-T technology platform independently developed by Legend Biotech. It employs endogenous TCR silencing technology blocking complex formation by expressing proteins that"  
[X Link](https://x.com/chuminhua432/status/1941061396588069293) [@chuminhua432](/creator/x/chuminhua432) 2025-07-04T09:07Z 2906 followers, 2836 engagements


"#Akeso announced that its independently developed first-in-class #bispecific #ADC #AK146D1 (Trop2/Nectin4 ADC) for the treatment of advanced solid tumors has completed the enrollment of its first patient in a Phase Ia clinical study in #China. The study is currently progressing in China Australia and other regions. AK146D1 is Akeso's first bispecific ADC to enter the clinical stage. AK146D1 received clinical trial approvals from the FDA the Australian TGA and China's NMPA"  
[X Link](https://x.com/chuminhua432/status/1960993381875867698) [@chuminhua432](/creator/x/chuminhua432) 2025-08-28T09:10Z 2906 followers, 2784 engagements


"#Epigenic Therapeutics a clinical-stage innovative drug development company today announced the completion of a $XX million Series B round of #financing led by Lapam Capital with continued participation from existing investors Qiming Venture Partners and OrbiMed and addition of new investors including IFSC and a renowned investment firm in the industry. This round of funding will primarily support the ongoing clinical development of EPI-003 for chronic hepatitis B functional cure and EPI-001 for hypercholesterolemia treatment. Epigenic focuses on developing next-generation gene modulation"  
[X Link](https://x.com/chuminhua432/status/1964989928468787325) [@chuminhua432](/creator/x/chuminhua432) 2025-09-08T09:51Z 2906 followers, 1067 engagements


"#Akeso announced that data from a Phase Ib/II clinical study evaluating the combination of cadonilimab (PD-1/CTLA-4) and pulocimab (an anti-VEGFR-2 antibody) in patients with immunotherapy (IO)-resistant NSCLC were presented in a Mini Oral session at #WCLC25. cadonilimab (PD-1/CTLA-4) + pulocimab (VEGFR-2) is a potentially chemo-free option for advanced IO resistant NSCLC patients. The trial enrolled both squamous and non-squamous NSCLC pts. As of January XX 2025 with a median follow-up of XXXX months the cadonilimab-based combination achieved a median overall survival (mOS) of XXXX months"  
[X Link](https://x.com/chuminhua432/status/1967527952398352779) [@chuminhua432](/creator/x/chuminhua432) 2025-09-15T09:56Z 2906 followers, 2768 engagements


"$ONC and $ABBV s Pharmacyclics have decided to voluntarily dismiss the patent lawsuit the Big Pharma firm brought against its competitor over their BTK inhibitors. BeOne announced the decision in a securities filing to HKSE. The move comes after the U.S. Patent and Trademark Office (USPTO) recently invalidated all claims of AbbVies patent No. 11672803 which underpinned the Illinois pharmas patent infringement lawsuit filed in 2023"  
[X Link](https://x.com/chuminhua432/status/1974136578315595864) [@chuminhua432](/creator/x/chuminhua432) 2025-10-03T15:36Z 2906 followers, XXX engagements


"Expedition Therapeutics Raises $XXX Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD Funding to advance EXPD-101 a Phase 2ready once-daily oral DPP1 inhibitor with first-in-class potential into a global development program in COPD and a broad spectrum of other neutrophil-driven diseases. In August 2025 Expedition acquired exclusive worldwide rights excluding mainland China Hong Kong and Macau from Fosun Pharma to develop and commercialize EXPD-101 in all indications"  
[X Link](https://x.com/chuminhua432/status/1976584810798993667) [@chuminhua432](/creator/x/chuminhua432) 2025-10-10T09:45Z 2906 followers, 2414 engagements


"#esmo2025 oral Multitude Therapeutics CD44v9 ADC AMT-116 Updated ongoing phase I/II clinical trial results of AMT-116 a first-in-class anti-CD44v9 antibody-drug conjugate (ADC) in patients with advanced solid tumors X mg/kg Q2W was determined as the RP2D dose in AMT-116-02 Among EGFR wild-type NSCLC patients (n=20; squamous/non-squamous) the objective response rate was XX% (6/20 X confirmed PR) and the disease control rate was XX% (17/20). TRAEs Grade X occurred in XXXX% of patients"  
[X Link](https://x.com/chuminhua432/status/1977677118705422726) [@chuminhua432](/creator/x/chuminhua432) 2025-10-13T10:05Z 2906 followers, 1008 engagements


"Kailera Therapeutics Announces $XXX Million Series B Financing Kailera Therapeutics details of which first emerged in May 2024 under the name Hercules CM NewCo emerged from stealth Tuesday with plans to develop a portfolio of GLP-1 drugs. The drugs were acquired from Jiangsu Hengrui Pharmaceuticals"  
[X Link](https://x.com/chuminhua432/status/1978392581731123206) [@chuminhua432](/creator/x/chuminhua432) 2025-10-15T09:28Z 2906 followers, 1032 engagements


"$DNTH a clinical-stage bio announced it has entered into an exclusive #licensing agreement with Nanjing Leads Biolabs for DNTH212 (being developed in China by Leads Biolabs as LBL-047) a first and potentially best-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor. DNTH212 is an investigational extended half-life bifunctional fusion protein. Now in Ph1. $XX million upfront + near-term milestone payments $X million milestone upon the initiation of a Dianthus-led Phase X study additional $XXX million in total development and regulatory approval milestones and sales-based milestones"  
[X Link](https://x.com/chuminhua432/status/1979080438317748723) [@chuminhua432](/creator/x/chuminhua432) 2025-10-17T07:02Z 2906 followers, 1577 engagements


"$GILD s Kite Pharma is doubling down on in vivo CAR-T this time inking a deal worth up to $XXXX billion biobucks with biotech Pregene Biopharma. $XXX million upfront + $XXXX billion milestone Pregene also helped AstraZeneca-owned EsoBiotec design its in vivo CAR-T. The Big Pharma bought out EsoBiotec back in March for up to $X billion dollars"  
[X Link](https://x.com/chuminhua432/status/1979089000267944072) [@chuminhua432](/creator/x/chuminhua432) 2025-10-17T07:36Z 2906 followers, 2279 engagements


"Today's 3rd biopharma out-licensing deal: Hansoh Pharma grants Roche an exclusive worldwide license (excluding the Chinese Mainland Hong Kong Macau and Taiwan) to its investigational CDH17-targeting ADC HS-20110. Hansoh Pharmawill receive an upfront payment of US$80 million and is eligible to receive milestone payments as well as royalties on potential future product sales. HS-20110 a CDH17-targeting ADCutilizing TOPOi payload. In Ph1 study for solid tumor"  
[X Link](https://x.com/chuminhua432/status/1979214577884893548) [@chuminhua432](/creator/x/chuminhua432) 2025-10-17T15:55Z 2906 followers, 1745 engagements


"#3SBio published the Ph2 results of SSGJ-707 #SSGJ707 a bispecific antibody targeting PD-1 and VEGF as a monotherapy in patients with advanced NSCLC . Among the XX pts completed at least one efficacy evaluation ORR and DCR were XXXX% (8/27)/85.2% (23/27) 61.8%(21/34)97.1% (33/34) XXXX% (6/11)/90.9% (10/11) and XX% (1/4)/75% (3/4) at doses of 5mg/kg Q3W 10mg/kg Q3W 20mg/kg Q3W and XX mg/kg Q3W respectively. Select subgroups are summarized in SSGJ-707 10mg/kg Q3W. The ORR were XXXX% (12/22) and 75%(9/12) in non-squamous and squamous pts respectively"  
[X Link](https://x.com/chuminhua432/status/1925826076023882183) [@chuminhua432](/creator/x/chuminhua432) 2025-05-23T08:08Z 2905 followers, 12K engagements


"Some media reported that Legend Biotech $LEGN has disbanded its Chinese sales and marketing team. On August XX 2024 #Carvykti (cilta-cel) was approved for marketing in #China becoming the sixth CAR-T cell therapy to be launched in China. In 2024 Carvykti's global sales revenue was $XXX million. $JNJ"  
[X Link](https://x.com/chuminhua432/status/1934554009940943349) [@chuminhua432](/creator/x/chuminhua432) 2025-06-16T10:09Z 2908 followers, 1413 engagements


"#Innovent Biologics announced Friday that #mazdutide a dual #glucagon/GLP-1 receptor agonist licensed from $LLY in 2019 was approved by Chinese #NMPA for chronic weight management in adults with overweight or obesity. The decision was based on data from the Chinese Phase III GLORY-1 trial which were presented #ADA2024 At week XX those taking the high dose saw placebo-adjusted weight loss of XX% which increased to XXXX% at week XX. Mazdutide is under NMPA review for type X diabetes In DREAMS-2 the high dose of mazdutide lowered HbA1c by XXXX% from baseline at XX weeks versus XXXX% for Trulicity"  
[X Link](https://x.com/chuminhua432/status/1938869972014637287) [@chuminhua432](/creator/x/chuminhua432) 2025-06-28T07:59Z 2909 followers, 1292 engagements


"#Innovent Biologics has registered a Phase III clinical trial for its novel Claudin18.2-targeting ADC drug #IBI343 for the treatment of pancreatic cancer The trial titled G-HOPE-002 plans to enroll XXX patients with advanced pancreatic cancer. IBI343 features a differentiated design. The ADC technology originates from a collaboration with Synaffix and utilizes glycan-mediated site-specific conjugation with a drug-to-antibody ratio (DAR) of X. It employs a highly internalizing antibody and incorporates Fc silencing mutations. In July Innovent officially disclosed the molecular structure of"  
[X Link](https://x.com/chuminhua432/status/1945331743558656304) [@chuminhua432](/creator/x/chuminhua432) 2025-07-16T03:56Z 2909 followers, 7905 engagements


"$PFE announced the completion of a global ex-China licensing agreement with 3SBio granting Pfizer exclusive rights for the development manufacturing and commercialization of 3SBios SSGJ-707 Additionally the agreement provides Pfizer the option to extend the license to include exclusive development and commercialization rights to SSGJ-707 in China. In exchange for the exclusive rights in China Pfizer will pay 3SBio up to $XXX million in option payments"  
[X Link](https://x.com/chuminhua432/status/1948752473646399903) [@chuminhua432](/creator/x/chuminhua432) 2025-07-25T14:29Z 2905 followers, XXX engagements


"#Innovent Biologics' U.S. subsidiary Fortvita Biologics has registered a Phase X clinical trial for the small-molecule GLP-1 receptor agonist #IBI3032 The Phase X trial plans to enroll XX healthy participants divided into X cohorts with each cohort consisting of X participants receiving IBI3032 or placebo in a 6:2. According to information disclosed by Innovent at this year's JPM IBI3032 is an oral small-molecule GLP-1 receptor agonist"  
[X Link](https://x.com/chuminhua432/status/1955980461236478199) [@chuminhua432](/creator/x/chuminhua432) 2025-08-14T13:10Z 2909 followers, 2028 engagements


"#Innovent Biologics' clinical trial application for #IBI3026 has been accepted by the #NMPA. IBI3026 is a fusion protein of a PD-1 antibody and IL-12. Some key facts about IBI 3026:"  
[X Link](https://x.com/chuminhua432/status/1958899966472065338) [@chuminhua432](/creator/x/chuminhua432) 2025-08-22T14:32Z 2909 followers, 1260 engagements


"#3SBio announced that its #IND application for #SA102 has been approved by #NMPA for the treatment of relapsed or refractory multiple myeloma. SA102 is a CS1/BCMA dual-target CAR-T therapies developed by Wuhan Sian Medical Tech. In Dec. 2023 3SBio and Sian signed a patent licensing agreement granting 3SBio exclusive rights in Greater China for the development registration manufacturing and commercialization of the drug. Previously SA102 completed an IIT at Wuhan Union Hospital. The study results showed that among all XX treated patients XX patients (ORR: 81%) achieved OR reaching minimal"  
[X Link](https://x.com/chuminhua432/status/1964003397566341537) [@chuminhua432](/creator/x/chuminhua432) 2025-09-05T16:31Z 2908 followers, XXX engagements


"#esmo2025 oral Biokin/SystImmune EGFR x HER3 ADC Iza-Bren (BL-B01D1) Phase I global study of Iza-Bren (BL-B01D1) an EGFR x HER3 bispecific antibody-drug conjugate (ADC) in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and other solid tumors D1D8 Q3W is summarized in the table. Promising efficacy was observed at XXX mg/kg in multiple tumor types with confirmed ORR (cORR) of XXXX% including NSCLC (cORR XXXX% N=14; cORR XXXX% for EGFR mutant N=11 and cORR XXXX% for EGFR wildtype N=3) and BC (cORR XXX% N=3)"  
[X Link](https://x.com/chuminhua432/status/1977675343856369792) [@chuminhua432](/creator/x/chuminhua432) 2025-10-13T09:58Z 2906 followers, 2350 engagements


"On Oct XX Biokin/SystImmune announced that the global Phase 2/3 pivotal registration clinical trial IZABRIGHT-Breast01 for its iza-bren (BL-B01D1 EGFRHER3 bispecific ADC) in collaboration with $BMY has achieved a milestone triggering the first $XXX million near-term contingent payment condition under the BMS collaboration agreement. The wholly-owned subsidiary SystImmune will receive the payment"  
[X Link](https://x.com/chuminhua432/status/1977681396798738920) [@chuminhua432](/creator/x/chuminhua432) 2025-10-13T10:22Z 2908 followers, XXX engagements


"$GSK announced that the NMPA has approved Shingrix (GSKs Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster) in adults aged XX years and over who are at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. the previous indication for adults aged XX and older"  
[X Link](https://x.com/chuminhua432/status/1978399314906141153) [@chuminhua432](/creator/x/chuminhua432) 2025-10-15T09:55Z 2908 followers, XXX engagements


"$IMAB announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences. The Company also announced the pending acquisition of VIS-101 a novel bifunctional biologic targeting VEGF-A and ANG2. The pending acquisition will be made by a newly formed subsidiary Visara Inc. (Visara) a NewCo focused on developing ophthalmic therapeutics for serious eye disorders and is expected to be completed later this month. VIS-101 (also named lASKG712) is developed by ASK pharma the"  
[X Link](https://x.com/chuminhua432/status/1979230110109831631) [@chuminhua432](/creator/x/chuminhua432) 2025-10-17T16:56Z 2908 followers, 2477 engagements


"While $IMAB's press release describes VIS-101 "to be acquired by Visara" ASK Pharma's Chinese listing announcement refers to it as a licensing agreement in licensed territories. According to ASK its controlling subsidiary AskGene Pharma has entered into a licensing agreement with Visara. AskGene Pharma grants Visara rights of its ASK G712 (VIS-101) within the licensed territories. The licensed regions include Greater China Singapore Thailand Malaysia Indonesia Vietnam South Korea and India. Visara will pay AskGene a one-time non-refundable upfront payment of $X million within XX business days"  
[X Link](https://x.com/chuminhua432/status/1979232899074580614) [@chuminhua432](/creator/x/chuminhua432) 2025-10-17T17:07Z 2908 followers, 1837 engagements


"$JNJ reported 2025 Q3 earnings XXX% sales increase to $XX billion BCMA CAR-T therapy Carvyktideveloped in partnership with Legend Biotechsaw significant sales growth. Carvykti achieved total sales of $XXX million in Q3 2025 marking an XXXX% yoy increase. Carvykti's sales have already surpassed $X billion this year totaling $XXXXX billion exceeded its full-year total from 2024 which was $XXX million"  
[X Link](https://x.com/chuminhua432/status/1978396388808593549) [@chuminhua432](/creator/x/chuminhua432) 2025-10-15T09:43Z 2905 followers, 2806 engagements


"#esmo2025 $SMMT Akeso PD-1/VEGF antibody #ivonescimab Ph3 HARMONi-6 trial results Achieve a Clinically Meaningful Benefit over Tislelizumab ( $ONC anti-PD-1 antibody) Combined with Chemotherapy in 1L NSCLC: Median PFS of XXXXX Months vs. XXXX Months HR 0.60"  
[X Link](https://x.com/chuminhua432/status/1980278974787035625) [@chuminhua432](/creator/x/chuminhua432) 2025-10-20T14:24Z 2905 followers, 1506 engagements


"#esmo2025 RemeGen reported the Ph3 RC48-C016 study in Presidential Symposium its HER2 ADC disitamab vedotin (DV) + toripalimab ( Junshi's PD-1 mab) vs chemo as 1L HER2-expressing la/m urothelial carcinoma median PFS: XXXX months vs XXX months reducing the risk of disease progression or death by XX% (HR =0.36 XX% CI: XXXX - XXXX P 0.0001). median OS: XXXX months vs XXXX months XX% reduction in the risk of death (HR = XXXX XX% CI: XXXX - XXXX P 0.0001) ORR assessed by BICR: XXXX% vs 50.2%"  
[X Link](https://x.com/chuminhua432/status/1980461853500404011) [@chuminhua432](/creator/x/chuminhua432) 2025-10-21T02:31Z 2905 followers, 1707 engagements


"$SMMT Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study Results Expansion of Summits Global Phase III Development Program Starts with Initiation of HARMONi-GI3 a New Study in 1L CRC"  
[X Link](https://x.com/chuminhua432/status/1980538069792235993) [@chuminhua432](/creator/x/chuminhua432) 2025-10-21T07:34Z 2905 followers, XXX engagements


"Samsung Bioepis and Phrontline Biopharma have entered into a global collaboration agreement on two ADC assets: TJ108 bispecific and dual-payload ADC and another asset to be named. In addition Samsung Bioepis will receive an exclusive license from Phrontline for one TOP1i payload which is applied to Samsung Bioepis ADC pipeline. #licensing Financial terms undisclosed Phrontline is a biotech focus on bispecific dual-payload ADCs"  
[X Link](https://x.com/chuminhua432/status/1980565331501543635) [@chuminhua432](/creator/x/chuminhua432) 2025-10-21T09:22Z 2905 followers, 1084 engagements


"BeOne Medicines (BeiGene) $ONC has recently registered a Ph2 study (CTR20252981) on #CDE for its independently developed #IRAK4 PROTAC degrader BGB-45035 vs placebo in patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to csDMARDs or bDMARDs/tsDMARDs. This is currently the only IRAK4 degrader drug in Phase II clinical trials globally. The primary clinical endpoint is the disease activity score based on C-reactive protein at Week XX. Other IRAK4 degrader in clinical trials: LT-002-158 Shanghai Leadingtac Pharma Ph1"  
[X Link](https://x.com/chuminhua432/status/1950454398578282866) [@chuminhua432](/creator/x/chuminhua432) 2025-07-30T07:12Z 2906 followers, 1307 engagements


"#Akeso said in its H1 2025 report its lung cancer drug ivonescimab (PD-1/EGFR) for the first time clearly extended overall survival (OS) in a pivotal study. The final analysis of the Phase III HARMONi-A trial met its OS goal showing that ivonescimab delivered "a statistically significant and clinically meaningful OS benefit.""  
[X Link](https://x.com/chuminhua432/status/1960530603306311912) [@chuminhua432](/creator/x/chuminhua432) 2025-08-27T02:31Z 2906 followers, 9745 engagements


"China Biopharma Tracker - September 2025 #apprvoal #ChinabioTracker Only X new novel drugs received their first marketing approval in September by China's NMPA both are from ex-China 1) Tzield (teplizumab) $SNY CD3 mab for type X diabetes 2) Fexuclue (fexuprazan) P-CAB Yangtze River Pharma licensed from Daewoong Pharma for gastroesophageal reflux disease X drugs approved for new indication including Mazdutide dual glucagon/GLP-1 receptor agonist for T2DM Innovent licensed the drug from $LLY And denosumab biosimiliar from Henlius Fosun' subsidiary appproved in both US and Europe in September"  
[X Link](https://x.com/chuminhua432/status/1975208988787740936) [@chuminhua432](/creator/x/chuminhua432) 2025-10-06T14:38Z 2905 followers, 3341 engagements


"#Vigonvita submitted its Hong Kong IPO prospectus on January XX 2025 which expired after six months on July XX and was resubmitted on July 31"  
[X Link](https://x.com/chuminhua432/status/1951225545376801174) [@chuminhua432](/creator/x/chuminhua432) 2025-08-01T10:16Z 2905 followers, XXX engagements


"#Minova Pharma completed a hundred-million RMB level Series B #financing exclusively led by IDG Capital. Minova's homegrown DCA (deoxycholic acid) injection wasapproved for market in China in June becoming China's first aproved fat-dissolving injection. The company continues to focus on the field of aesthetic-related diseases with new drugs for s androgenetic alopecia and photoaging set to enter clinical development in Q4 2025. In the field of mental health the anti-postpartum depression drug MI078 capsule has completed Phase II clinical studies"  
[X Link](https://x.com/chuminhua432/status/1959861496076517690) [@chuminhua432](/creator/x/chuminhua432) 2025-08-25T06:12Z 2905 followers, XXX engagements


"#MagicRNA announced the completion of nearly RMB100 million in Pre-A+ #financing led by IDG Capital. The funds will be used for the IND filing and IITs of the lead asset #HN2301. Founded in December 2021 MagicRN focuses on nucleic acid drug delivery and therapeutic mRNA innovative drugs. The company has developed a ionizable amino lipid library with the lipid (ILB3132) already commercialized. In 2023 MagicRNA successfully established an engineered cell delivery platform (Engineered Cell Targeted LNP EnC-LNP). The in vivo CAR-T HN2301 developed based on the EnC-LNP platform enter the clinical"  
[X Link](https://x.com/chuminhua432/status/1961368049984180742) [@chuminhua432](/creator/x/chuminhua432) 2025-08-29T09:59Z 2905 followers, 7424 engagements


"#esmo2025 Kelun-Biotech TROP2 ADC sacituzumab tirumotecan (sac-TMT) which out-licensed to $MRK in 2022 for ex-Greater China rights Phase X OptiTROP-Lung04 trial: in EGFR-mutated NSCLC following progression on EGFR-TKIs receive sac-TMT monotherapy or chemotherapy median PFS of XXX months versus XXX months OS was not reached XX% lower risk of death"  
[X Link](https://x.com/chuminhua432/status/1980286505164915145) [@chuminhua432](/creator/x/chuminhua432) 2025-10-20T14:54Z 2905 followers, 1425 engagements


"#esmo2025 Merck KGaA and Abbisko Therapeutics Pimicotinib (ABSK021) small-molecule inhibitor of CSF-1R Phase X MANEUVER trial results With median follow-up of XXXX months pimicotinib demonstrated increasing ORR over time from XX% at Week XX to XXXX% Pimicotinib has been granted breakthrough therapy designation (BTD) for the treatment of inoperable TGCT by China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA) and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck KGaA Darmstadt Germany holds worldwide"  
[X Link](https://x.com/chuminhua432/status/1980468795484545126) [@chuminhua432](/creator/x/chuminhua432) 2025-10-21T02:58Z 2905 followers, 1187 engagements


"$ZLAB Zai Lab has registered its first Ph3 clinical trial of ZL-1310 (zocilurtatug pelitecan) This randomized open-label clinical trial (n=665) aims to evaluate the efficacy and safety of ZL-1310 (at two dose levels) compared with investigator's choice (Tarlatamab Topotecan Lurbinectedin or Amrubicin) in patients with relapsed SCLC. The primary endpoints are cORR and OS. ZL-1310 is an ADC targeting DLL3 discovered by MediLink Therapeutics using its TAMLIN technology platform. In April 2023 Zai Lab and MediLink Therapeutics entered an agreement acquiring global rights for ZL-1310. In ASCO2025"  
[X Link](https://x.com/chuminhua432/status/1980616444850368962) [@chuminhua432](/creator/x/chuminhua432) 2025-10-21T12:45Z 2905 followers, 2260 engagements


"Hong Kong Stock Exchange web shows that Vigonvita has passed the hearing and is about to be listed"  
[X Link](https://x.com/chuminhua432/status/1980617744359084282) [@chuminhua432](/creator/x/chuminhua432) 2025-10-21T12:50Z 2905 followers, XXX engagements